2023.09.27 MediciNova Announces Results of Studies under BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury MN-166joint development
2023.03.09 MediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury MN-166joint development
2022.06.30 MediciNova Announces Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury MN-166joint development
2021.03.10 MediciNova Announces Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury MN-166joint development
2021.03.03 MediciNova Announces Update on SARS-CoV-2 Vaccine for COVID-19 clinical trialsjoint development
2020.11.24 MediciNova Announces Initiation of Master Virus Seed Stock Production for its Intranasal COVID-19 Vaccine using BC-PIV Vector Technology clinical trialsjoint development
2020.09.23 MediciNova Announces that its Intranasal COVID-19 Vaccine Successfully Induced Systemic IgG and Mucosal IgA Neutralizing Antibodies Against SARS-CoV-2 in Mice using BC-PIV Vector Technology clinical trialsjoint development
2020.09.01 MediciNova Announces Development Progress on Intranasal Formulation of SARS-CoV-2 Vaccine for COVID-19 clinical trialsjoint development
2020.07.27 MediciNova Announces SARS-CoV-2 Vaccine Joint Development with BioComo and Mie University Japan clinical trialsjoint development
